Report overview
Lung cancer can be categorized into two types: non-small cell lung cancer and small cell lung cancer. Small cell lung cancer constitutes roughly 10-15 percent of all diagnosed cases of lung cancer. Small cell lung cancer is categorized into two types: small cell carcinoma and combined small cell carcinoma. It can be further classified into two stages: limited-stage small cell lung cancer and extensive-stage small cell lung cancer. Small cell lung cancer is caused by smoking tobacco, or second hand smoking, or on exposure to asbestos, chromium, arsenic, nickel, soot, or radon. The common symptoms associated with lung cancer are chest pain, incurable cough, blood in sputum, fatigue, loss of appetite, unintentional weight loss, shortness of breath, and wheezing. Small cell lung cancer has a poor prognosis and gets diagnosed only at the late stage of disease progression, and hence, has a high mortality rate. There are no therapies available to cure small cell lung cancer in the market.
This report aims to provide a comprehensive presentation of the global market for Small Cell Lung Cancer Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Small Cell Lung Cancer Therapeutics. This report contains market size and forecasts of Small Cell Lung Cancer Therapeutics in global, including the following market information:
Global Small Cell Lung Cancer Therapeutics Market Revenue, 2019-2024, 2024-2029, ($ millions)
Global top five companies in 2023 (%)
The global Small Cell Lung Cancer Therapeutics market was valued at US$ million in 2023 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2023, While China is to reach $ Million.
Biologics Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Small Cell Lung Cancer Therapeutics include Sanofi, Bristol-Myers Squibb, GlaxoSmithKline, Menarini, Ziopharm Oncology, Merck, Novartis, AstraZeneca and Takeda Pharmaceutical, etc. in 2023, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Small Cell Lung Cancer Therapeutics companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Small Cell Lung Cancer Therapeutics Market, by Type, 2019-2024, 2024-2029 ($ millions)
Global Small Cell Lung Cancer Therapeutics Market Segment Percentages, by Type, 2023 (%)
Biologics
Small Molecules
Global Small Cell Lung Cancer Therapeutics Market, by Application, 2019-2024, 2024-2029 ($ millions)
Global Small Cell Lung Cancer Therapeutics Market Segment Percentages, by Application, 2023 (%)
Hospitals
Clinics
Other
Global Small Cell Lung Cancer Therapeutics Market, By Region and Country, 2019-2024, 2024-2029 ($ Millions)
Global Small Cell Lung Cancer Therapeutics Market Segment Percentages, By Region and Country, 2023 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Small Cell Lung Cancer Therapeutics revenues in global market, 2019-2024 (estimated), ($ millions)
Key companies Small Cell Lung Cancer Therapeutics revenues share in global market, 2023 (%)
Further, the report presents profiles of competitors in the market, key players include:
Sanofi
Bristol-Myers Squibb
GlaxoSmithKline
Menarini
Ziopharm Oncology
Merck
Novartis
AstraZeneca
Takeda Pharmaceutical
Teva Pharmaceutical
Eli Lilly
Mylan
Sun Pharmaceuticals Industries
Amgen
Ono Pharmaceutical
Shanghai Jinhe Bio-Technology
Outline of Major Chapters:
Chapter 1: Introduces the definition of Small Cell Lung Cancer Therapeutics, market overview.
Chapter 2: Global Small Cell Lung Cancer Therapeutics market size in revenue.
Chapter 3: Detailed analysis of Small Cell Lung Cancer Therapeutics company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Small Cell Lung Cancer Therapeutics in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
